Serina Therapeutics has opened a Phase 1b clinical trial of SER-252, a subcutaneous apomorphine candidate built on the company’s POZ polymer platform, following FDA IND clearance in January. The first patient has been dosed in adults with Parkinson’s disease and motor fluctuations, and the study will evaluate safety, tolerability, pharmacokinetics, and exploratory efficacy. To finance the next phase of execution, Serina entered into a private placement of up to $30 million with 50% warrant coverage and has already received $16 million in gross proceeds, supplemented by an active at-the-market program that has raised $12.9 million to date. The company ended 2025 with $3.1 million in cash, underscoring the importance of this capital to sustain clinical momentum.
The strategic question is whether a polymer-enabled, depot-like delivery of a known dopaminergic agent can credibly rival device-aided therapies and pump-based regimens now scaling in advanced Parkinson’s. If SER-252 can achieve continuous dopaminergic stimulation through intermittent subcutaneous dosing with acceptable tolerability, it could offer a less complex alternative to infusion systems and surgery, potentially broadening access and easing clinic workflow. That bar, however, is high. Movement disorder specialists will expect robust, durable reductions in off time and dyskinesia, clean injection-site profiles, and evidence that the pharmacokinetics translate into meaningful daily function gains without new safety liabilities.
For patients and caregivers, the promise is regimen simplicity and fewer rescue interventions; for payers, the value proposition must extend beyond convenience. In an era where subcutaneous levodopa-carbidopa pumps and optimized device strategies are gaining traction, reimbursement will hinge on comparative benefit and total-cost offsets such as reduced hospitalizations, lower ancillary medication use, and diminished caregiver burden. Medical Affairs will need to guide precise patient selection and generate early real-world evidence to bridge beyond exploratory MDS-UPDRS signals toward outcomes and utilization data that support access and formulary placement. Competitors in continuous dopaminergic delivery, as well as oral adjuncts and device makers, will watch closely for any sign that a minimally managed injectable can erode pump or DBS share in specific subpopulations.
The financing structure reflects the current biotech market’s pragmatism: insider-led capital with warrants to balance risk, paired with opportunistic ATM usage. It buys time for a data-driven inflection but also pressures the program to deliver clear de-risking in 2026. The platform narrative adds optionality. POZ aims to control drug loading and release kinetics across modalities, with an existing non-exclusive license to Pfizer for LNP formulations hinting at broader partnering potential. Beyond Parkinson’s, Serina’s once-weekly VMAT2 inhibitor candidate for tardive dyskinesia targets a practical gap by aligning with long-acting antipsychotic administration and addressing dysphagia and adherence barriers that challenge current oral VMAT2 therapies.
What to watch next is unambiguous: dose-escalation safety and PK demonstrating steady, predictable exposure; injection-site tolerability strong enough to support repeated administration; and early, directional efficacy that justifies rapid advancement into outcomes-focused studies. Clarity on regulatory pathway—particularly the feasibility of a 505(b)(2) strategy anchored in apomorphine’s established pharmacology—will shape timelines, capital needs, and partnering calculus. The broader industry test is whether platform-enabled reformulations can secure premium pricing and durable market share amid intensifying payer scrutiny, or whether they must tie early to real-world evidence and service models to displace entrenched device and infusion competitors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
